請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19054
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 江伯倫(Bor-Luen Chiang) | |
dc.contributor.author | Si-Sim Kang | en |
dc.contributor.author | 江序心 | zh_TW |
dc.date.accessioned | 2021-06-08T01:43:33Z | - |
dc.date.copyright | 2020-08-27 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-19 | |
dc.identifier.citation | 1. Nombela-Arrieta, C., J. Ritz, and L.E. Silberstein, The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol, 2011. 12(2): p. 126-31. 2. Sheng, G., The developmental basis of mesenchymal stem/stromal cells (MSCs). BMC Dev Biol, 2015. 15: p. 44. 3. Romanov, Y.A., et al., Mesenchymal stem cells from human bone marrow and adipose tissue: isolation, characterization, and differentiation potentialities. Bull Exp Biol Med, 2005. 140(1): p. 138-43. 4. Dominici, M., et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy Position Statement. Cytotherapy, 2006. 8(4): p. 315-7. 5. Chan, W.K., et al., MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. Exp Hematol, 2008. 36(11): p. 1545-55. 6. Kim, N. and S.G. Cho, Overcoming immunoregulatory plasticity of mesenchymal stem cells for accelerated clinical applications. Int J Hematol, 2016. 103(2): p. 129-37. 7. Lee, D.K. and S.U. Song, Immunomodulatory mechanisms of mesenchymal stem cells and their therapeutic applications. Cell Immunol, 2018. 326: p. 68-76. 8. Ghannam, S., et al., Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol, 2010. 185(1): p. 302-12. 9. Akiyama, K., et al., Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell, 2012. 10(5): p. 544-55. 10. Li, Y.P., et al., Human mesenchymal stem cells license adult CD34(+) hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the notch pathway. J Immunol, 2008. 180(3): p. 1598-1608. 11. Melief, S.M., et al., Multipotent stromal cells skew monocytes towards an anti-inflammatory function: the link with key immunoregulatory molecules. Haematologica, 2013. 98(9): p. e121-2. 12. Nemeth, K., et al., Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med, 2009. 15(1): p. 42-9. 13. Ren, G., et al., Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2008. 2(2): p. 141-50. 14. Lazarus, H.M., et al., Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant, 1995. 16(4): p. 557-64. 15. Zappia, E., et al., Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 2005. 106(5): p. 1755-1761. 16. Connick, P., et al., The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials, 2011. 12. 17. Llufriu, S., et al., Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One, 2014. 9(12): p. e113936. 18. Duijvestein, M., et al., Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut, 2010. 59(12): p. 1662-9. 19. Elgaz, S., et al., Clinical use of mesenchymal stromal cells in the treatment of acute graft-versus-host disease. Transfus Med Hemother, 2019. 46(1): p. 27-34. 20. Bowlus, C.L. and M.E. Gershwin, The diagnosis of primary biliary cirrhosis. Autoimmun Rev, 2014. 13(4-5): p. 441-4. 21. Khanna, A., et al., Symptoms of PBC - pathophysiology and management. Best Pract Res Clin Gastroenterol, 2018. 34-35: p. 41-47. 22. Bogdanos, D.P., et al., Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol, 2004. 40(1): p. 31-9. 23. Wang, J.J., et al., Escherichia coli infection induces autoimmune cholangitis and anti-mitochondrial antibodies in non-obese diabetic (NOD).B6 (Idd10/Idd18) mice. Clin Exp Immunol, 2014. 175(2): p. 192-201. 24. Rieger, R. and M.E. Gershwin, The X and why of xenobiotics in primary biliary cirrhosis. J Autoimmun, 2007. 28(2-3): p. 76-84. 25. Rieger, R., et al., Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun, 2006. 27(1): p. 7-16. 26. Lleo, A., et al., Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology, 2010. 52(3): p. 987-998. 27. Juran, B.D. and K.N. Lazaridis, Environmental factors in primary biliary cirrhosis. Semin Liver Dis, 2014. 34(3): p. 265-72. 28. Joshita, S., et al., Genetics and epigenetics in the pathogenesis of primary biliary cholangitis. Clin J Gastroenterol, 2018. 11(1): p. 11-18. 29. Ercilla, G., et al., Primary biliary cirrhosis associated with HLA-DRw3. Tissue Antigens, 1979. 14(5): p. 449-52. 30. Donaldson, P.T., et al., HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study. Hepatology, 2006. 44(3): p. 667-74. 31. Hirschfield, G.M., et al., Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med, 2009. 360(24): p. 2544-55. 32. McNally, R.J., et al., Seasonal variation in the patient diagnosis of primary biliary cirrhosis: further evidence for an environmental component to etiology. Hepatology, 2011. 54(6): p. 2099-103. 33. Varyani, F.K., J. West, and T.R. Card, An increased risk of urinary tract infection precedes development of primary biliary cirrhosis. BMC Gastroenterol, 2011. 11: p. 95. 34. Neuberger, J., Antibodies and primary biliary cirrhosis - piecing together the jigsaw. J Hepatol, 2002. 36(1): p. 126-9. 35. Hirschfield, G.M. and M.E. Gershwin, The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol, 2013. 8: p. 303-30. 36. Amano, K., et al., Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol, 2005. 174(9): p. 5874-83. 37. Wakabayashi, K., et al., Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology, 2008. 48(2): p. 531-40. 38. Selmi, C., et al., Innate immunity and primary biliary cirrhosis. Curr Mol Med, 2009. 9(1): p. 45-51. 39. Lleo, A., et al., Primary biliary cholangitis: a comprehensive overview. Hepatol Int, 2017. 11(6): p. 485-499. 40. Wu, S.J., et al., Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology, 2011. 53(3): p. 915-925. 41. Gulamhusein, A.F. and G.M. Hirschfield, Pathophysiology of primary biliary cholangitis. Best Pract Res Cl Ga, 2018. 34-35: p. 17-25. 42. Rong, G., et al., Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol, 2009. 156(2): p. 217-225. 43. Mao, T.K., et al., Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology, 2005. 42(4): p. 802-8. 44. Kita, H., et al., Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology, 2002. 123(4): p. 1031-43. 45. Wu, S.-J., et al., Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology (Baltimore, Md.), 2011. 53(3): p. 915-925. 46. Shimoda, S., et al., The role of natural killer (NK) and NK T cells in the loss of tolerance in murine primary biliary cirrhosis. Clin Exp Immunol, 2012. 168(3): p. 279-84. 47. Shuai, Z., et al., Adaptive immunity in the liver. Cell Mol Immunol, 2016. 13(3): p. 354-68. 48. Colucci, G., F. Schaffner, and F. Paronetto, In situ characterization of the cell-surface antigens of the mononuclear cell infiltrate and bile duct epithelium in primary biliary cirrhosis. Clin Immunol Immunopathol, 1986. 41(1): p. 35-42. 49. Kita, H., et al., Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest, 2002. 109(9): p. 1231-40. 50. Ambrosini, Y.M., et al., The multi-hit hypothesis of primary biliary cirrhosis: polyinosinic-polycytidylic acid (poly I:C) and murine autoimmune cholangitis. Clin Exp Immunol, 2011. 166(1): p. 110-20. 51. Lan, R.Y., et al., Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun, 2009. 32(1): p. 43-51. 52. Lan, R.Y., et al., Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology, 2006. 43(4): p. 729-37. 53. Achenza, M.I., et al., Serum autoantibodies for the diagnosis and management of autoimmune liver diseases. Expert Rev Gastroenterol Hepatol, 2012. 6(6): p. 717-29. 54. Shi, T.Y. and F.C. Zhang, Role of autoimmunity in primary biliary cirrhosis. World J Gastroenterol, 2012. 18(48): p. 7141-8. 55. Hirschfield, G.M., et al., Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology, 2015. 148(4): p. 751-U347. 56. Chascsa, D., E.J. Carey, and K.D. Lindor, Old and new treatments for primary biliary cholangitis. Liver Int, 2017. 37(4): p. 490-499. 57. Wang, L., et al., Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. Stem Cells Dev, 2014. 23(20): p. 2482-2489. 58. Wang, L.F., et al., A pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. J Gastroenterol Hepatol, 2013. 28: p. 85-92. 59. Fan, J., et al., Mesenchymal stem cells alleviate experimental autoimmune cholangitis through immunosuppression and cytoprotective function mediated by galectin-9. Stem Cell Res Ther, 2018. 9(1): p. 237. 60. Wang, D., et al., Effect of allogeneic bone marrow-derived mesenchymal stem cells transplantation in a polyI:C-induced primary biliary cirrhosis mouse model. Clin Exp Med, 2011. 11(1): p. 25-32. 61. Liu, X., et al., Heterogeneity of MSC: origin, molecular identities, and functionality. Stem Cells Int, 2019. 2019: p. 9281520. 62. Yu, H.C. and B.L. Chiang, Toll-like receptor 2 ligation of mesenchymal stem cells alleviates asthmatic airway inflammation. J Allergy Clin Immunol, 2018. 142(1): p. 284-287 e5. 63. Hsueh, Y.H., et al., Endogenous IL-10 maintains immune tolerance but IL-10 gene transfer exacerbates autoimmune cholangitis. J Autoimmun, 2018. 95: p. 159-170. 64. Tsuchiya, A., et al., Mesenchymal stem cell therapies for liver cirrhosis: MSCs as 'conducting cells' for improvement of liver fibrosis and regeneration. Inflamm Regen, 2019. 39: p. 18. 65. Petrenko, Y., et al., A comparative analysis of multipotent mesenchymal stromal cells derived from different sources, with a focus on neuroregenerative potential. Sci Rep, 2020. 10(1): p. 4290. 66. Watanabe, Y., et al., Mesenchymal stem cells and induced bone marrow-derived macrophages synergistically improve liver fibrosis in mice. Stem Cells Transl Med, 2019. 8(3): p. 271-284. 67. Chen, Y., et al., Recruitment of endogenous bone marrow mesenchymal stem cells towards injured liver. J Cell Mol Med, 2010. 14(6B): p. 1494-508. 68. Nasir, G.A., et al., Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice. J Transl Med, 2013. 11: p. 78. 69. Corpechot, C., R. Poupon, and O. Chazouilleres, New treatments/targets for primary biliary cholangitis. JHEP Rep, 2019. 1(3): p. 203-213. 70. Tsuda, M., et al., Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology, 2012. 55(2): p. 512-21. 71. Harada, K., et al., Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol, 2009. 157(2): p. 261-70. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19054 | - |
dc.description.abstract | 原發性膽管炎(Primary biliary cholangitis)為慢性自體免疫肝炎,患者體內產生高量的自體抗體——抗粒線體抗體(anti-mitochondrial antibodies),此抗體的出現會加速膽道的破壞,導致膽管發炎、免疫細胞浸潤至肝臟門脈三角,並加速肝臟纖維化、肝硬化的發生。目前針對原發性膽管炎的療法主要是透過抑制膽汁外溢誘發的症狀來改善患者病況,本研究希望藉由間質幹細胞(Mesenchymal stem cell)療法,調節疾病上游的免疫反應,進而影響疾病進程。間質幹細胞為具有自我更新(self-renewal)與多功能分化能力(multipotency)的全能幹細胞,近年有許多研究指出間質幹細胞具有免疫調節的能力,我們透過試管內測試驗證了培養出具有正確性質的間質幹細胞。接著,利用以注射外源物質2-octynoic acid (OA)-ovalbumin (OVA) 誘發原發性膽管炎的模式小鼠,以尾靜脈注射的方式給予間質幹細胞,分析疾病晚期小鼠肝臟的免疫細胞浸潤情形、免疫細胞組成以及肝臟纖維化程度。研究結果顯示,儘管靜脈注射間質幹細胞對血清中抗粒線體抗體的濃度沒有影響,也不影響各淋巴球亞群的活化程度,但此療法能降低T細胞的浸潤,使浸潤的免疫細胞組成趨向未發病小鼠的情形。同時,為了使間質幹細胞的同源性增加、促進其免疫調節性質,我們測試了以類鐸受體-2(TLR-2)之配體(ligand)Pam3CSK4預先處理的間質幹細胞,將其應用於原發性膽管炎的疾病模式,發現處理後的間質幹細胞在in vitro實驗中,對於T細胞的抑制有更強的效果,同時可以抑制原發性膽管炎小鼠肝臟之T細胞分泌發炎性細胞激素的能力。然而,使用於小鼠疾病模式的治療並無顯著的效果。 | zh_TW |
dc.description.abstract | Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by the high level of circulating anti-mitochondrial antibodies (AMA), which results in immune cell infiltration in the liver portal area and causing inflammation and damage of the bile duct. Current medicine for PBC including ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) was used to ameliorate the cholestatic symptoms, however, still a large portion of the patients are unresponsive to these drugs. In this study, we proposed a therapeutic strategy via infusing mesenchymal stem cells (MSC) to modulate the inflammation caused by autoimmunity. Studies have suggested that MSCs exert anti-inflammatory and immunomodulatory functions that have been applied to various disease models and clinical trials. We followed the previously established protocol of 2-octynoic acid (OA)-ovalbumin (OVA) immunized PBC model. After culturing and characterizing MSCs, we injected the cells into the immunized mice in the early stages of the disease progression. After MSC infusion, PBC mice have decreased in the T cell population and increased in NKT cells, however, the treatment did not alter the level of anti-mitochondrial antibodies, and did not affect the number of activated lymphocyte subpopulations. Further, a previous study from our lab had demonstrated that the pre-treatment of TLR-2 ligand, Pam3CSK4, promoting homogeneity in the MSC population and enhanced the immunoregulation property of MSCs. We then applied the Pam3CSK4-treated MSCs on the PBC model and evaluated the therapeutic efficacy of the treatment. our data indicated that the proliferation of T cells within the liver leukocytes isolated from the PBC mice reduced the most in the Pam3CSK4-treated MSC group. Moreover, the Pam3CSK4-polarized MSCs reduced the activation sensitivity of CD4 and CD8 T cells and reduced the expression level of TNF-α from the liver tissue of PBC mice. However, Pam3CSK4-polarized MSCs did not have a significant effect on the PBC mice. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T01:43:33Z (GMT). No. of bitstreams: 1 U0001-1708202019343900.pdf: 4040344 bytes, checksum: b861e868c9e1a62f019d2ad73548c012 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 致謝 I 中文摘要 II ABSTRACT III TABLE OF CONTENTS IV TABLE OF FIGURES VII I INTRODUCTION 2 1 Mesenchymal stem cells (MSCs) 2 1.1 Characterization of MSCs 2 1.2 Immunomodulatory function of MSCs 2 1.3 MSC as a therapeutic approach 3 2 Primary biliary cholangitis (PBC) 4 2.1 The risk factors of PBC 5 2.2 The pathology of PBC 6 2.3 The therapeutic strategy of PBC 7 2.4 MSC-based therapies of PBC 8 3 Hypothesis and specific aim 9 II MATERIALS AND METHODS 11 4 Materials 11 4.1 Mice 11 4.2 MSC culture 11 4.3 Flow cytometry 11 4.4 T lymphocyte proliferation assay 12 4.5 MSC differentiation 12 4.6 Cell staining assay 12 4.7 Enzyme-linked immunosorbent assay (ELISA) 13 4.8 RNA extraction 13 4.9 Reverse transcription-polymerase chain reaction (RT-PCR) 13 4.10 Quantitative real-time PCR (qPCR) 13 5 Methods 15 5.1 Isolation of MSC 15 5.2 MSC cell sub-culturing 15 5.3 MSC characterization 15 5.4 Isolation of CD4+ T lymphocytes 15 5.5 T lymphocyte proliferation assay 16 5.6 MSC differentiation assay and cell staining 16 5.7 Induction of primary biliary cholangitis and MSC administration 16 5.8 Liver mononuclear cells quantitation and functional assay 17 5.9 RNA extraction 17 5.10 Reverse transcription-polymerase chain reaction (RT-PCR) 17 5.11 Anti-PDC-E2 antibody measurement 17 5.12 Statistical analysis 18 III RESULTS 20 1 Experimental design and MSC characterization 20 2 2-OA-OVA-immunized mice shown infiltration of immune cells and fibrosis in liver. 20 3 MSC administration altered the lymphocyte population of PBC mice 21 4 MSCs affect the fibrosis and inflammatory status of PBC mice 22 5 Pam3CSK4-treated MSCs enhanced the immunosuppressive property of MSCs 23 6 Pam3CSK4-treated MSCs had little effect on the composition and activation of lymphocytes in the liver of the PBC mice 24 7 MSCs and Pam3CSK4-treated MSCs decreased the IL-17A cytokine production from the LMNC of PBC 24 IV DISCUSSION AND CONCLUSION 27 REFERENCES 31 FIGURES 40 | |
dc.language.iso | en | |
dc.title | 探討以間質幹細胞應用到原發性膽管炎的治療 | zh_TW |
dc.title | The therapeutic application of mesenchymal stem cells on primary biliary cholangitis | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 莊雅惠(Ya-Hui Chuang),朱清良(Ching-Liang Chu) | |
dc.subject.keyword | 間質幹細胞,原發性膽管炎,細胞治療, | zh_TW |
dc.subject.keyword | Mesenchymal stem cell,primary biliary cholangitis,Cell therapy, | en |
dc.relation.page | 56 | |
dc.identifier.doi | 10.6342/NTU202003846 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2020-08-19 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 免疫學研究所 | zh_TW |
顯示於系所單位: | 免疫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1708202019343900.pdf 目前未授權公開取用 | 3.95 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。